{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:49:07Z","timestamp":1790682547137,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T00:00:00Z","timestamp":1563667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology Reports"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.gore.2019.07.010","type":"journal-article","created":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T10:55:15Z","timestamp":1565434515000},"page":"118-122","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer"],"prefix":"10.1016","volume":"29","author":[{"given":"Elizabeth K.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenying","family":"Tan-Wasielewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula A.","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Birrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexi A.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis A.","family":"Konstantinopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce F.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gore.2019.07.010_bb0005","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/1078-0432.CCR-14-3068","article-title":"Dual targeting of protein degradation pathways with the selective HDAC6 inhibitor ACY-1215 and bortezomib is synergistic in lymphoma","author":"Amengual","year":"2015","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.gore.2019.07.010_bb0010","doi-asserted-by":"crossref","first-page":"26729","DOI":"10.1074\/jbc.C500186200","article-title":"Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors","volume":"280","author":"Bali","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gore.2019.07.010_bb0015","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/ncb3582","article-title":"ARID1A-mutated ovarian cancers depend on HDAC6 activity","volume":"19","author":"Bitler","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.gore.2019.07.010_bb0020","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1101\/gad.436407","article-title":"HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates","volume":"21","author":"Boyault","year":"2007","journal-title":"Genes Dev."},{"key":"10.1016\/j.gore.2019.07.010_bb0025","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s10637-010-9467-6","article-title":"The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines","volume":"29","author":"Budman","year":"2011","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.gore.2019.07.010_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-0788-2","article-title":"Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d\/PI3K\/AKT\/mTOR and ERK pathways","volume":"9","author":"Cao","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.gore.2019.07.010_bb0035","first-page":"539","article-title":"Histone deacetylase inhibitors enhance paclitaxel-induced cell death in ovarian cancer cell lines independent of p53 status","volume":"24","author":"Chobanian","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/j.gore.2019.07.010_bb0040","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.gore.2019.07.010_bb0045","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jpainsymman.2018.08.017","article-title":"Phenotypic characterization of paclitaxel-induced peripheral neuropathy in cancer survivors","volume":"56","author":"Kober","year":"2018","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.gore.2019.07.010_bb0050","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/j.pain.0000000000000893","article-title":"HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy","volume":"158","author":"Krukowski","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.gore.2019.07.010_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-017-02390-7","article-title":"Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer","volume":"8","author":"Qi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gore.2019.07.010_bb0060","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bcp.2015.11.005","article-title":"4-Hydroxybenzoic acid derivatives as HDAC6-specific inhibitors modulating microtubular structure and HSP90\u03b1 chaperone activity against prostate cancer","volume":"99","author":"Seidel","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.gore.2019.07.010_bb0065","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.2217\/fon.11.124","article-title":"Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers","volume":"7","author":"Singh","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.gore.2019.07.010_bb0070","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nbd.2017.11.011","article-title":"Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth","volume":"111","author":"Van Helleputte","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.gore.2019.07.010_bb0075","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1158\/0008-5472.CAN-17-1467","article-title":"Peripheral neuropathy induced by microtubule-targeted chemotherapies: insights into acute injury and long-term recovery","volume":"78","author":"Wozniak","year":"2018","journal-title":"Cancer Res."}],"updated-by":[{"DOI":"10.1016\/j.gore.2021.100703","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000}}],"container-title":["Gynecologic Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578919300724?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352578919300724?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T01:55:35Z","timestamp":1762480535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352578919300724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":15,"alternative-id":["S2352578919300724"],"URL":"https:\/\/doi.org\/10.1016\/j.gore.2019.07.010","relation":{},"ISSN":["2352-5789"],"issn-type":[{"value":"2352-5789","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gore.2019.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}